Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| N.makhviladzis Sakhelob… | Healthcare Services | 5.9% | 37th pct | 268 |
| Tbilisis Diagnostikuri … | Healthcare Services | -450.0% | 1st pct | 268 |
| Pediatriuli Kirurgiis T… | Healthcare Services | — | no FY data | 268 |
| Med-Diagnostika | Healthcare Services | — | no FY data | 268 |
| Atlas Medical | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | N.makhviladzis Sakhelob… | Tbilisis Diagnostikuri … | Pediatriuli Kirurgiis T… | Med-Diagnostika | Atlas Medical |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 100.0% | -150.0% | — | — | — |
| EBITDA Margin | 5.9% | -450.0% | — | — | — |
| EBITDAR | 25 | -45 | — | — | — |
| EBITDAR Margin | 5.9% | -450.0% | — | — | — |
| EBIT Margin | 3.3% | -450.0% | — | — | — |
| Net Profit Margin | 3.3% | 3380.0% | — | — | — |
| Operating Expense % of Sales | 94.1% | 300.0% | — | — | — |
| Returns | |||||
| Return on Assets (ROA) | 0.9% | 29.5% | — | — | — |
| Return on Equity (ROE) | 0.9% | 29.7% | — | — | — |
| ROIC [EBIT / Invested Capital] | 1.0% | -4.0% | — | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | — | — | — |
| Debt-to-Equity | 0.00x | 0.00x | — | — | — |
| Debt-to-EBITDA | 0.00x | N/A | — | — | — |
| Equity-to-Assets | 100.0% | 99.4% | — | — | — |
| Net Debt | -28 | -13 | — | — | — |
| Cash & Equivalents | 28 | 13 | — | — | — |
| Total Debt | N/A | N/A | — | — | — |
| Liquidity & working capital | |||||
| Current Ratio | N/A | 163.57x | — | — | — |
| Quick Ratio | N/A | 163.57x | — | — | — |
| Cash Ratio | N/A | 1.86x | — | — | — |
| Total Current Assets | 189 | 1,145 | — | — | — |
| Total Current Liabilities | N/A | 7 | — | — | — |
| Inventory | N/A | N/A | — | — | — |
| Trade Receivables | 151 | 1,132 | — | — | — |
| Trade Payables | N/A | 7 | — | — | — |
| Net Working Capital | 189 | 1,138 | — | — | — |
| Net Working Capital % of Revenue | 45.0% | 11380.0% | — | — | — |
| Trade Working Capital | 151 | 1,125 | — | — | — |
| Trade Working Capital % of Revenue | 36.0% | 11250.0% | — | — | — |
| Change in Trade Working Capital | N/A | N/A | — | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | — | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | — | — | — |
| Receivables Turnover | 2.78x | 0.01x | — | — | — |
| Days Sales Outstanding (DSO) | 131.5 | 41318.0 | — | — | — |
| Payables Turnover | N/A | 3.57x | — | — | — |
| Days Payable Outstanding (DPO) | N/A | 102.2 | — | — | — |
| Cash Conversion Cycle | 131.5 days | 41215.8 days | — | — | — |
| Asset Turnover | 0.29x | 0.01x | — | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 420 | -69 | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | 14 | 93 | — | — | — |
| Cash Conversion (OCF / EBITDA) | 1696.9% | N/A | — | — | — |
| Dividends Declared | N/A | N/A | — | — | — |
| Dividend Payout Ratio | N/A | N/A | — | — | — |